Last updated: July 31, 2026
OctreoScan, an indium In-111 pentetreotide diagnostic radiopharmaceutical, is a mature nuclear-medicine product facing structural decline from gallium-68 and copper-64 somatostatin-receptor PET agents. Its FDA exclusivity and meaningful patent protection expired long ago. The product retains demand where PET access is limited, but its commercial role is increasingly narrow. Product-level revenue is not separately disclosed, preventing a reliable standalone sales estimate. Financial value now depends on installed imaging infrastructure, radiopharmacy distribution, supply reliability, and residual demand rather than exclusivity.
What is OctreoScan and how is it used?
OctreoScan is a single-photon-emission computed tomography, or SPECT, diagnostic agent containing indium In-111 pentetreotide. It binds to somatostatin receptors and is used to localize primary and metastatic somatostatin-receptor-positive neuroendocrine tumors in adults and children.
The product is supplied as a kit for preparation of the radiolabeled injection. Its use requires:
- A supply of indium In-111.
- Radiopharmacy compounding capability.
- Gamma-camera or SPECT imaging equipment.
- Specialized nuclear-medicine distribution.
- Coordination around the product’s radioactive decay profile.
The FDA approved OctreoScan in 1994 under NDA 020928. The product has been associated with Mallinckrodt Nuclear Medicine LLC and the Curium nuclear-medicine business. FDA labeling identifies the product as an indium In-111 pentetreotide kit for intravenous administration. (FDA, 2024a)
What is the FDA regulatory status of OctreoScan?
OctreoScan remains an FDA-approved diagnostic radiopharmaceutical under NDA 020928. It is not a biologic and therefore does not face biosimilar competition. Competitive products enter through their own new-drug applications rather than through the biosimilar pathway.
| Regulatory item |
OctreoScan status |
| Active ingredient |
Indium In-111 pentetreotide |
| Dosage form |
Radiolabeled injectable solution prepared from a kit |
| FDA application |
NDA 020928 |
| Initial U.S. approval |
1994 |
| Therapeutic area |
Somatostatin-receptor imaging and neuroendocrine tumors |
| Regulatory class |
Small-molecule diagnostic radiopharmaceutical |
| Biosimilar pathway |
Not applicable |
| Primary technology |
SPECT imaging |
| Main newer competitors |
Netspot and Detectnet |
OctreoScan’s original indication was broader in historical practice than the current commercial market. The product’s use has increasingly concentrated on patients who require somatostatin-receptor imaging but do not have practical access to PET radiopharmaceuticals.
When did OctreoScan lose exclusivity?
OctreoScan lost meaningful regulatory exclusivity decades ago. A 1994 approval would have exhausted the five-year new-chemical-entity exclusivity period by approximately 1999, subject to the regulatory framework applicable at the time. Any patent protection tied to the original product, radiolabeling process, or diagnostic use would also have expired by now unless an unusual later patent applied.
The commercial question is therefore not whether OctreoScan has remaining exclusivity. It does not have a modern exclusivity position comparable with recently approved oncology drugs. The relevant barriers are operational:
- Radioisotope supply.
- Manufacturing and kit release.
- Nuclear-pharmacy distribution.
- Short product shelf life.
- Imaging-center availability.
- Physician familiarity.
- Reimbursement and local clinical protocols.
What patents protect OctreoScan?
No active, commercially material patent estate is generally associated with OctreoScan’s original product today. The active ingredient, indium In-111 pentetreotide, has been commercially established for decades, and any original composition or formulation patents would have expired.
The Orange Book is the relevant source for checking listed patents and regulatory exclusivity associated with FDA-approved drugs. OctreoScan’s competitive position is not based on an unexpired Orange Book patent blocking generic or alternative diagnostic entry. The product is instead protected by manufacturing know-how, radiopharmacy operations, supply contracts, quality systems, and distribution capabilities.
Are there formulation patents for OctreoScan?
The kit formulation has technical requirements involving peptide stability, radiolabeling, excipients, sterility, and product release. Those requirements can create manufacturing complexity, but formulation complexity is not the same as enforceable patent exclusivity.
The main practical barriers are:
- Validated sterile manufacturing.
- Consistent indium In-111 sourcing.
- Radiochemical purity control.
- Radioactive-material handling.
- Distribution within the product’s usable time window.
- Compliance with FDA current good manufacturing practice requirements.
These barriers can limit the number of suppliers even when no blocking patent remains.
How does OctreoScan compare with Netspot and Detectnet?
OctreoScan competes with PET agents that target the same somatostatin receptor pathway but use different radionuclides and imaging platforms.
| Product |
Active radiolabeled agent |
Imaging modality |
FDA approval |
Commercial position |
| OctreoScan |
Indium In-111 pentetreotide |
SPECT |
1994 |
Mature, declining |
| Netspot |
Gallium Ga-68 dotatate |
PET |
2016 |
Major modern alternative |
| Detectnet |
Copper Cu-64 dotatate |
PET |
2020 |
Expanding PET alternative |
Netspot established a higher-resolution PET-based alternative for imaging somatostatin-receptor-positive gastroenteropancreatic neuroendocrine tumors. Detectnet added a copper-64 platform with a longer physical half-life than gallium-68, which can improve scheduling and distribution flexibility in some settings. FDA approved Netspot and Detectnet for localization of somatostatin-receptor-positive lesions, including those associated with neuroendocrine tumors. (FDA, 2016; FDA, 2020)
Why are PET agents taking share from OctreoScan?
PET generally provides higher sensitivity, higher spatial resolution, faster image acquisition, and stronger integration with contemporary oncology imaging workflows than SPECT. PET agents also benefit from growing investment in theranostics, particularly the pairing of diagnostic somatostatin-receptor imaging with radioligand therapies such as lutetium Lu-177 dotatate.
OctreoScan remains relevant in facilities without reliable access to Ga-68 or Cu-64 PET. That installed-base dependence creates a residual market but limits long-term growth.
What is the market outlook for OctreoScan?
The market is a mature replacement and access-driven market rather than a growth market. Demand is shaped by three forces.
PET substitution
The principal source of volume erosion is migration from indium In-111 SPECT to Ga-68 and Cu-64 PET. As hospitals add PET/CT capacity and radiopharmaceutical networks expand, OctreoScan loses scans to newer agents.
Neuroendocrine tumor growth
The incidence and diagnosis of neuroendocrine tumors have increased over time, creating more demand for somatostatin-receptor imaging. This growth supports the overall target-imaging category but does not fully offset OctreoScan’s modality disadvantage.
Regional access differences
OctreoScan has stronger residual utility in markets where:
- PET scanners are scarce.
- Ga-68 generator or cyclotron capacity is limited.
- Cu-64 distribution is unavailable.
- Nuclear-medicine departments retain SPECT infrastructure.
- Reimbursement favors established local protocols.
Its geographic performance is therefore uneven. The product can remain commercially viable in selected regions even as its strategic position deteriorates in advanced PET markets.
What is OctreoScan’s financial trajectory?
OctreoScan’s standalone revenue, gross margin, and operating profit are not publicly reported as separate line items by the product owner. Public-company filings generally aggregate nuclear imaging products or report broader business segments. The absence of product-level disclosure prevents a defensible estimate of annual OctreoScan sales.
The financial trajectory can nevertheless be characterized:
| Period |
Financial and market condition |
| 1990s |
Established diagnostic product with limited direct competition |
| 2000s |
Mature nuclear-imaging product with recurring institutional demand |
| 2010s |
Increasing competitive pressure from PET development |
| 2016 onward |
Netspot accelerates substitution toward Ga-68 PET |
| 2020 onward |
Detectnet adds Cu-64 PET competition |
| Current market |
Residual demand, infrastructure-dependent sales, limited pricing power |
Revenue quality is likely more important than revenue growth. Radiopharmaceutical products can generate recurring orders, but profitability is exposed to low volumes, radioactive logistics, manufacturing interruptions, isotope costs, and fixed compliance expenses.
The product’s financial value is also affected by portfolio economics. A supplier may retain OctreoScan because it shares manufacturing, regulatory, distribution, and customer-service infrastructure with other nuclear-medicine products. That can support continued availability even when standalone growth is negative.
What generic entry risks exist for OctreoScan?
Traditional generic-entry risk is limited because OctreoScan is an old diagnostic product with no apparent blocking exclusivity. The more relevant risk is competitive substitution by newer branded radiopharmaceuticals.
Potential entrants would face:
- FDA approval requirements for a radiopharmaceutical kit.
- Sterile manufacturing validation.
- Radioisotope sourcing.
- Specialized facility licensing.
- Nuclear-pharmacy logistics.
- Limited shelf life.
- Customer switching costs.
- Reimbursement and clinical adoption requirements.
A new indium In-111 pentetreotide supplier could compete on price or supply reliability, but the addressable market is constrained by PET migration. That makes investment in a direct copy less attractive than investment in PET agents or theranostic platforms.
Which companies are challenging OctreoScan?
The most important competitive challenge comes from Curium’s Netspot franchise and Novartis’s Detectnet product, rather than from a conventional generic manufacturer.
The competitive landscape includes:
- Curium Pharma, associated with OctreoScan and Netspot through its nuclear-medicine portfolio.
- Advanced Accelerator Applications, a Novartis company associated with Netspot and the broader radioligand-therapy ecosystem.
- Inom, associated with Detectnet commercialization in the United States.
- Regional radiopharmaceutical manufacturers and nuclear pharmacies.
- Future developers of somatostatin-receptor PET and theranostic agents.
Netspot creates an internal portfolio substitution risk if the same supplier markets both legacy SPECT and newer PET products. Portfolio owners may preserve OctreoScan for access-limited accounts while directing growth investment toward PET and therapeutic radioligand products.
What patent litigation or Paragraph IV challenges affect OctreoScan?
No major contemporary Paragraph IV litigation or high-value patent dispute is central to OctreoScan’s market position. The product’s primary threat is technological replacement, not patent enforcement.
Because OctreoScan has no meaningful modern exclusivity position, a Paragraph IV challenge would offer limited strategic value unless it targeted an unexpired listed patent associated with a particular formulation or use. The commercial market is already open to competing diagnostic agents, and the strongest competitors have entered through differentiated PET products rather than simple copies.
What settlement agreements or licensing deals affect OctreoScan?
No prominent publicly disclosed patent settlement is central to OctreoScan’s current economics. Its ownership history and commercial availability are more relevant than patent settlements.
The strategic licensing environment is concentrated around:
- PET radiopharmaceutical supply.
- Gallium-68 and copper-64 isotope access.
- Theranostic platforms.
- Hospital and nuclear-pharmacy distribution.
- Manufacturing and contract-production arrangements.
For investors and licensors, the higher-value assets are newer somatostatin-receptor PET diagnostics and linked therapeutic programs, not the legacy OctreoScan franchise.
How strong is the OctreoScan patent estate?
OctreoScan’s patent estate is weak as a source of exclusivity and moderate as a source of operational know-how.
| Patent-estate dimension |
Assessment |
| Composition protection |
Expired or commercially immaterial |
| Formulation protection |
No apparent current blocking position |
| Method-of-use protection |
No apparent durable exclusivity |
| Orange Book leverage |
Limited |
| Manufacturing know-how |
Relevant |
| Regulatory know-how |
Relevant |
| Distribution capability |
Highly relevant |
| Litigation deterrence |
Low |
| Long-term moat |
Weak |
The product’s defensibility depends on execution. A supplier with dependable isotope access, validated production, and broad nuclear-pharmacy coverage can retain customers despite the absence of patent exclusivity.
What generic launch scenarios are plausible?
Three scenarios define the remaining market.
Base case: managed decline
OctreoScan volumes decline gradually as PET capacity expands. The product remains available for institutions without PET access and for physicians who continue using SPECT-based protocols.
Downside case: accelerated substitution
Supply interruptions, reimbursement changes, or expanded availability of Netspot and Detectnet accelerate conversion to PET. In this scenario, the product becomes a low-volume maintenance asset.
Stabilization case: access-market persistence
Shortages of PET agents, limited PET infrastructure, or favorable pricing preserve a stable residual customer base. This would support continued sales but would not restore historical strategic importance.
What is the commercial investment thesis for OctreoScan?
OctreoScan is best viewed as a cash-generating legacy diagnostic asset rather than a growth product. Its value lies in recurring demand and portfolio synergies, not in patent-protected pricing or market expansion.
Key commercial risks include:
- PET substitution.
- Product discontinuation or supply interruption.
- Falling scan volumes.
- Pricing pressure from alternative agents.
- Increased reliance on a shrinking SPECT installed base.
- Manufacturing economics at lower volumes.
Potential support factors include:
- Neuroendocrine tumor diagnosis growth.
- Continued SPECT availability.
- Regional PET shortages.
- Established physician familiarity.
- Portfolio bundling with other nuclear diagnostics.
Key Takeaways
- OctreoScan is an FDA-approved indium In-111 pentetreotide SPECT diagnostic, originally approved in 1994 under NDA 020928.
- Its meaningful regulatory and patent exclusivity expired decades ago.
- No current patent estate appears to provide material commercial blocking power.
- Netspot and Detectnet are the primary modern competitors, using Ga-68 and Cu-64 PET technology.
- Product-level revenue is not separately disclosed, but the financial trajectory is consistent with mature-market decline.
- Residual demand depends on regions and hospitals without reliable PET access.
- Generic-entry risk is less important than technological substitution.
- Manufacturing, isotope sourcing, radiopharmacy distribution, and quality systems are the principal operational barriers.
- The asset remains commercially useful as a legacy product but has limited long-term growth value.
FAQs
Is OctreoScan still FDA approved?
Yes. OctreoScan remains associated with FDA NDA 020928 as an indium In-111 pentetreotide diagnostic kit.
Is OctreoScan a biologic?
No. OctreoScan is a radiolabeled peptide diagnostic and is regulated as a drug, not as a biologic. Biosimilar competition does not apply.
What replaced OctreoScan?
Ga-68 dotatate PET, marketed as Netspot, and Cu-64 dotatate PET, marketed as Detectnet, are the principal newer alternatives for somatostatin-receptor imaging.
Does OctreoScan have active Orange Book patents?
OctreoScan does not appear to have a commercially meaningful current patent position comparable with recently approved branded drugs. Its competitive barriers are operational rather than patent-based.
Can OctreoScan sales grow?
Sustained broad-based growth is unlikely. Sales can remain stable or increase temporarily in markets with limited PET capacity, supply constraints affecting PET agents, or continued reliance on SPECT infrastructure.
References
- U.S. Food and Drug Administration. (2016). NETSPOT (gallium Ga 68 dotatate injection) prescribing information.
- U.S. Food and Drug Administration. (2020). DETECTNET (copper Cu 64 dotatate injection) prescribing information.
- U.S. Food and Drug Administration. (2024a). OCTREOSCAN (indium In 111 pentetreotide) kit prescribing information.
- U.S. Food and Drug Administration. (2024b). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- Curium Pharma. (2024). Nuclear medicine product information and company materials.
- Mallinckrodt plc. (2023). Annual report and Form 10-K filings.
